Literature DB >> 15508450

[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].

Toru Ishikawa1, Ken-ichi Mizuno, Kouji Watanabe, Yasuyuki Baba, Hironobu Oota, Toshiaki Yoshida, Tomoteru Kamimura.   

Abstract

We report a case of a 43-year-old man with liver metastasis of advanced pancreatic cancer successfully treated with intra-arterial regional chemotherapy. The patient was admitted to our hospital suffering from anorexia and back pain. Abdominal CT showed pancreatic tail cancer with liver and Schnitzler metastasis. We decided a curative operation was impossible. Then, enteric-coated tegafur/uracil (400 mg) was administered. Simultaneously, intraarterial infusion with CDDP, 5-fluorouracil (500 mg) and infusion of gemcitabine (1,000 mg) with 50 microg of AT-II was given once a week. After 3 courses, the pancreatic tumor was reduced and the tumor markers decreased. Multiple metastatic liver tumors remarkably decreased. As a result, the maximum diameter of the pancreatic tumor decreased from 7 cm to 5 cm on the CT-scan. Serum carbohydrate antigen 19-9 (CA19-9) decreased from 122,000 U/ml to 10,200 U/ml. Moreover, the performance status of patient also improved. He was able to receive outpatient treatment despite his terminal cancer. Furthermore, the patient can take sufficient meals without any adverse effects. His quality of life has been preserved. This regimen could well be effective for advanced pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15508450

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

Review 1.  Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 2.  Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer?

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.